AbbVie Inc AbbVie (NYSE: ABBV) Announces FDA Extended Review Period for Upadacitinib’s NDA AbbVie Inc. (NYSE: ABBV) declared that FDA has made the decision regarding the supplemental New Drug Application (sNDA) for upadacitinib. FDA has decided that it will extend the review period for sNDA for upadacitinib.
Evolus Inc Evolus (NASDAQ: EOLS), AbbVie, And Medytox Resolve All Outstanding Litigation Evolus, Inc. (NASDAQ: EOLS), AbbVie (NYSE: ABBV), and Medytox disclosed that the firms have entered into a resolution deal.
